ELISA / EIA / RIA Kits · ELISA / EIA kit · Cat. EK-070-94
Exendin-4 (Heloderma suspectum) – EIA Kit
Supplied as 96 wells per unit. Species: Heloderma Suspectum. Technical values shown are imported catalog fields and should be confirmed against current documentation. Laboratory research use only.
Specifications
| Catalog number | EK-070-94 |
|---|---|
| Product type | ELISA / EIA / RIA Kits · ELISA / EIA kit |
| Peptide family | Exendins (Exendin-3, Exendin-4) |
| Species | Heloderma Suspectum |
| Unit size | 96 wells |
| Sensitivity | 0.08 ng/ml |
| Specificity | Peptide % Exendin-4 (Heloderma Suspectum) 100 Exendin-3 (9-39)-NH2 100 Exendin-4 (3-39) 100 Lixisenatide 100 Glucagon (Human, Rat, Mouse, Porcine, Bovine) 0 GLP-1 (7-36)-NH2 (Human, Rat, Mouse) 0 GLP-1 (7-37) (Human, Rat, Mouse) 0 GLP-2 (Human) 0 Oxyntomodulin (Human, Rat, Mouse) 0 |
| Linear Range | 0.08 - 0.86 ng/ml |
| Inter-Assay CV | <15% |
| Intra-Assay CV | <10% |
| Standard Curve | To reduce background noise for this kit, do not add EDTA to your samples.Heparin can be used as an alternative to EDTA for this kit. C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice. Tang D, Tian H, Wu J, et al. J Pharmacol Sci. 2018;138(1):23-30. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner. Liu J, Yang K, Xiao W, et al. Peptides. 2018;106:83-90. The use of low molecular weight protamine to enhance oral absorption of exenatide. Zhang L, Shi Y, Song Y, et al. Int J Pharm. 2018;547(1-2):265-273. Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility. Lee JG, Ryu JH, Kim SM, et al. Biochem Pharmacol. 2018;151:59-68. Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation. Chen C, Zheng H, Xu J, Shi X, Li F, Wang X. Daru. 2017;25(1):20. In vitro and in vivo characterization of a novel long-acting GLP-1 receptor agonist, exendin-4–Fc fusion protein Lian Lu, Xiaoqing Su, Yantai Wang et al., RSC Adv., 2017,7, 54178-54187 An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide. Kim D, Jeon H, Ahn S, Choi WI, Kim S, Jon S. J Control Release. 2017;256:114-120. Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats. Chen T, Kagan L, Mager DE. J Pharm Sci. 2013;102(10):3844-51. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. Chuang EY, Nguyen GT, Su FY, et al. Biomaterials. 2013;34(32):7994-8001. Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats. Xuan J, Lin Y, Huang J, et al. Peptides. 2013;46:172-9. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. Ahn S, Lee IH, Lee E, Kim H, Kim YC, Jon S. J Control Release. 2013;170(2):226-32. Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model. Kim PH, Lee M, Kim SW. J Control Release. 2012;162(1):9-18. Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes. Di pasquale G, Dicembrini I, Raimondi L, et al. PLoS ONE. 2012;7(7):e40074. Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. Gong N, Ma A-N, Zhang L-J, et al. British Journal of Pharmacology. 2011;163(2):399-412. Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats. Gao W, Jusko WJ. The Journal of Pharmacology and Experimental Therapeutics. 2011;336(3):881-890. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. Chae SY, Jin CH, Shin JH, et al. J Control Release. 2010;142(2):206-13. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. Kamei N, Morishita M, Takayama K. J Control Release. 2009;136(3):179-86. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Samson SL, Gonzalez EV, Yechoor V, Bajaj M, Oka K, Chan L. Mol Ther. 2008;16(11):1805-12. |
| Sample Extraction | recommended |
| Intended use | In vitro laboratory research only — not for human or veterinary use, diagnostic or therapeutic purposes |
Storage & handling
Store the kit at 4°C
Frequently asked
What is Exendin-4 (Heloderma suspectum) – EIA Kit?
Exendin-4 (Heloderma suspectum) – EIA Kit is a elisa / eia kit elisa / eia / ria kit listed under catalog number EK-070-94 in the Exendins (Exendin-3, Exendin-4) family, heloderma suspectum sequence. It is supplied as 96 wells per unit for in vitro laboratory research.
How should Exendin-4 (Heloderma suspectum) – EIA Kit be stored?
Store the kit at 4°C
What is the intended use of EK-070-94?
This catalog listing is for laboratory research use only. It is not represented as a drug, food, supplement, cosmetic or diagnostic product, and it is not offered for human or veterinary use.
This page reproduces an imported research-catalog record. Verify identity, specifications, documentation and suitability before purchase. The item is offered only for laboratory research and is not represented for human or veterinary use.